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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal and aggressive malignancies with a 5-year survival rate 
less than 9%. Early detection is particularly difficult due to the lack of symptoms even in advanced stages. microRNAs 
(miRs/miRNAs) are small (~ 18–24 nucleotides), endogenous, non-coding RNAs, which are involved in the pathogenesis of 
several malignancies including PDAC. Alterations of miR expressions can lead to apoptosis, angiogenesis, and metastasis. 
The role of environmental pollutants such as cadmium (Cd) in PDAC has been suggested but not fully understood. This study 
underlines the role of miRs (miR-221, miR-155, miR-126) in response to cadmium chloride  (CdCl2) in vitro. Lethal concen-
tration (LC50) values for  CdCl2 resulted in a toxicity series of AsPC-1 > HPNE > BxPC-3 > Panc-1 = Panc-10.5. Following 
the treatment with  CdCl2, miR-221 and miR-155 were significantly overexpressed, whereas miR-126 was downregulated. 
An increase in epithelial–mesenchymal transition (EMT) via the dysregulation of mesenchymal markers such as Wnt-11, 
E-cadherin, Snail, and Zeb1 was also observed. Hence, this study has provided evidence to suggest that the environmental 
pollutant Cd can have a significant role in the development of PDAC, suggesting a significant correlation between miRs and 
Cd exposure during PDAC progression. Further studies are needed to investigate the precise role of miRs in PDAC progres-
sion as well as the role of Cd and other environmental pollutants.
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ADAM9  ADAM metallopeptidase domain 9
CA 19-9  Carbohydrate antigen 19-9
Cd  Cadmium
CdCl2  Cadmium chloride 2
DEVD peptide  Aspartyl-L-glutamyl-L-valyl-L-aspartic 
acid amide
EMT  Epithelial mesenchymal transition
EMT-TFs  EMT-inducing transcription factors
FBS  Foetal bovine serum
FOXO1  Forkhead box protein O1
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HPNE  Human pancreatic nestin-expressing
HRP  Horseradish peroxidase
LC50  Lethal concentration 50%; concentration 
that will be lethal to half the population 
of cells
MAPK  Mitogen-activated protein kinase
microRNAs  MiRs/miRNAs
mRNA  Messenger RNA
NF-κβ  Nuclear factor kappa-light-chain-
enhancer of activated B cells
P53  Tumour protein P53
PanIN  Pancreatic intraepithelial neoplasia
PARP  Poly (ADP-ribose) polymerase
PCa  Pancreatic cancer
PDAC  Pancreatic ductal adenocarcinoma
PDGF  Platelet-derived growth factor
PTEN  Phosphatase and tensin homolog
RPII  RNA polymerase II
SD  Standard deviation
SIRT1  Sirtuin 1
STAT3  Signal transducer and activator of tran-
scription 3
TGF-β  Transforming growth factor beta
TNM  Tumour-node-metastasis
UTRs  Untranslated regions
Introduction
PDAC is the deadliest and most prevalent pancreatic cancer 
(PCa) type, which accounts for 90% of PCa cases (Von Hoff 
et al. 2009; Hidalgo et al. 2015). PDAC can be characterized 
as a “silent killer” and presents the worst prognosis between 
all cancer types due to the widespread metastasis that 
patients appear at the time of diagnosis, which is usually in 
late stages of malignancy (Bortesi et al. 2011). Only a small 
portion of PDAC patients can benefit from chemotherapy, 
due to severe toxic effects of the current therapies (Abbru-
zzese 2008). Especially in advanced stages, the chemothera-
peutics options are limited with gemcitabine being the first 
drug treatment with improvement in the median survival 
only by a few weeks (Scara et al. 2015; Xu et al. 2015). 
Carbohydrate antigen 19-9 (CA 19-9) is the most common 
diagnostic biomarker for PDAC in the last 30 years (Chan 
et al. 2014); nevertheless, CA 19-9 cannot be characterized 
as a PDAC-specific biomarker, especially for symptomless 
patients (Chan et al. 2014).
Interest in the role of Cd as a toxic metal ubiquitously 
present in the environment has risen during the last decades, 
especially with the reference to its possible role in various 
human diseases, especially carcinomas (Anđelković et al. 
2021; Buha et al. 2018, 2019, 2020). Its possible role in 
PDAC has been recently reviewed by Buha et al. (2017) 
suggesting multiple mechanisms responsible for Cd actions 
leading to the development of PDAC. The three predominant 
toxic mechanisms proposed are the alterations in the redox 
status of the cell, changes in the apoptotic pathways, and 
epigenetic changes. Further research which was a synergy 
of human observational, experimental, and in vitro stud-
ies showed Cd deposition in pancreatic tissue and revealed 
Cd-induced disturbances in intrinsic pathway of apoptotic 
activity and elevated oxidative stress in PDAC cells (Djord-
jevic et al. 2019). Further studies conducted on PDAC cell 
lines indicated that the mitochondria may be a site of action 
for Cd in promoting tumour development (Wallace et al. 
2019). Such findings clearly point towards Cd exposure as 
an important risk factor for PDAC development.
Preliminary studies suggested a correlation between aber-
rant expression levels of numerous miRs and PDAC (Yu 
et al. 2012). miRs, small (18–28 nucleotides-long), endog-
enous, non-coding, evolutionary conserved, single-stranded 
RNA molecules, shown to moderate gene expression at the 
post-transcriptional level through the binding to the com-
plementary sequences of their target messenger RNAs 
(mRNAs) at the 3′ untranslated regions (3′ UTRs) (Bartel 
2004). Based on the interactions between the 3′ UTRs of 
mRNAs, miRs can control the expression levels of several 
genes, while they can also regulate a number of cell signal-
ling pathways, which are related to several malignancies (Lin 
and Gregory 2015; Meltzer 2005; Słotwiński et al. 2018). 
Consequently, alterations in miRs expression can have as an 
outcome, apoptosis, angiogenesis, and metastasis (Amirkhah 
et at. 2015).
miR-221 is one of the most oncogenic miRs in PDAC 
alongside miR-21 (Bloomston et al. 2007; Uysal-Onganer 
et al. 2021; Yang et al. 2016; Zhang et al. 2008), while the 
overexpression of miR-221 has been correlated to a number 
of malignancies, such as hepatocellular carcinoma, pros-
tate adenocarcinoma, and colorectal carcinoma (Liu et al. 
2014; Tao et al. 2014; Yau et al. 2014; Zheng et al. 2014). 
Enhanced expression levels of miR-221 are closely associ-
ated with platelet-derived growth factor (PDGF)-mediated 
epidermal–mesenchymal transition phenotype, migration, 
metastasis, and uncontrolled proliferation of PDAC cells 
through the inhibition of both mitogen-activated protein 
kinase (MAPK) and transformation of growth factor β 
(TGF-β) signalling pathways (Masamune et al. 2013; Su 
et al. 2013; Mortoglou et al. 2021a, b). EMT can be char-
acterized as a key component of the metastatic cascade, 
which includes the repression of E-cadherin and the activa-
tion of genes related to motility and invasion (Kalluri and 
Weinberg 2009). Therefore, the examination of the most 
commonly expressed miRs with their related signalling 
pathways and their associated target genes is crucial for a 
better understanding of PDAC pathophysiology. Further-
more, upregulation in the expression of miR-155 has been 
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also found in PDAC tissue samples (Papaconstantinou et al. 
2013). Elevated levels in the expression of miR-155 can 
result in poor survival in PDAC patients due to the develop-
ment of fibrogenesis, through TGF-β (Greither et al. 2010; 
Mortoglou et al 2021a,b), while overexpression of this miR 
has been also associated with an increased progression from 
pancreatic intraepithelial neoplasia 2 (PanIN-2) to PanIN-3 
(Ryan et al. 2014). On the other hand, miR-126 is a tumour 
suppressor miR, which has been linked to PDAC progres-
sion, through the post-transcriptional upregulation of KRAS 
(Jiao et al. 2012) and HER2 (Garajová et al. 2014). HER2 
overexpression is observed in more than 30% of PDAC cases 
(Komoto et al. 2009; Mortoglou et al. 2021a,b).
In metastatic process, EMT is responsible for the loss of 
epithelial cell polarity and cell–cell adhesion (Brabletz et al. 
2018; Ye et al. 2017), while studies have shown that miRs 
are linked to the moderation of EMT, stem cell-like differen-
tiation, invasiveness, migration, and proliferation (Piasecka 
et al. 2018; Mortoglou et al. 2021a, b). Specifically, EMT 
is involved in increased tumorigenesis, invasiveness, and 
metastatic predisposition of several solid tumours including 
prostate, lung, liver, pancreatic, and breast cancers (Hugo 
et al. 2007; Lee et al. 2006; Ribatti et al. 2020). In numerous 
malignancies, EMT can be induced by hypoxia, growth fac-
tors regulated by tumour microenvironment, stroma cross-
talk, metabolic changes, and innate and adaptive immune 
responses (Roche 2018).
Wnt-11 is one of the noncanonical Wnt family members, 
which are activated during carcinogenesis and correlated to 
a poor prognosis of various cancer types including PDAC 
(Uysal-Onganer et al. 2010; Arisan et al. 2020; Guo and 
Wang 2009). During EMT, overexpression of the mesenchy-
mal marker Snail and the decrease of the epithelial marker 
E-cadherin has been noticed (Lin et al. 2010; Nakamura 
and Tokura 2011). Particularly, E-cadherin is a protein, 
which is necessary for the normal epithelial cell mainte-
nance, whereas transcriptional factors including Zeb1 and 
Snail are highly expressed through the binding in E-cadherin 
promoter (Felipe Lima et al. 2016; Lamouille et al. 2014; 
Seton-Rogers 2016; Singh and Settleman 2010). Therefore, 
transcription factors such as Snail and Zeb1 are key players 
of EMT (Stemmler et al. 2019). Moreover, EMT is regulated 
via molecular pathways, which are linked to both oncogenic 
and tumour suppressor non-coding RNAs, chromatin remod-
elling, epigenetic and posttranslational modifications, alter-
native splicing events, and protein stability (De Craene and 
Berx 2013; Fedele et al. 2017). Wnt-11 overexpression has 
been observed in PDAC tissues compared to normal adja-
cent tissues and is associated with tumour-node-metastasis 
(TNM) staging (Wang et al. 2018a, b). Especially, higher 
levels of Wnt-11 are correlated to stages II, III, and IV 
(Wang et al. 2016). On the other hand, Zeb1 upregulation is 
correlated to advanced PDAC stages and poor malignancy 
outcome (Arumugam et al. 2009; Buck et al. 2007; Maier 
et al. 2010). Zeb1 is also responsible not only for the acqui-
sition of an EMT phenotype but also for migration and 
invasion in response to nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κβ) signalling in PDAC 
cells (Maier et al. 2010). Furthermore, downregulation of 
E-cadherin is associated with poor prognosis and differen-
tiation in PDAC (Iacobuzio-Donahue et al. 2009; Winter 
et al. 2008), while elevated expression levels of Snail have 
been found to be related to 80% of PDAC cases (Hotz et al. 
2007). Besides, Snail overexpression is connected to reduced 
E-cadherin expression, higher tumour grade, and poorly dif-
ferentiated PDAC cell lines (Hotz et al. 2007).
Recently, mounting evidence has shown that heavy met-
als, including Cd, might exert their toxicity through miRs 
(Wallace et al. 2020). Hence, this study aimed to investigate 
miR expressions in response to Cd in metastatic PDAC cells. 
Subsequently, due to the fact that EMT markers could be 
proven a novel target for anticancer therapy, we also exam-
ined the expression levels of Wnt-11, E-cadherin, Snail, and 
Zeb1 following Cd exposure in PDAC in vitro.
Methodology
Pancreatic cell cultures and cadmium treatment
The cell lines are obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA). Control pancreas 
cells [hTERT-HPNE (“human pancreatic Nestin-expressing” 
cells or HPNE; ATCC ® CRL-4023™, control pancreatic 
cells)] and tumour [AsPC-1 (ATCC ® CRL-1682™, pancre-
atic tumour cells), Panc-1 (ATCC #CRL-1469™, Pancreas 
ductal epithelioid carcinoma), Panc-10.05 (ATCC #CRL-
2547™, Pancreatic epithelial adenocarcinoma), and BxPC-3 
(ATCC #CRL-1687™, Pancreatic adenocarcinoma)] were 
grown and maintained as described in the ATCC-suggested 
protocols. Unless otherwise specified, cells were grown in 
their defined optimum growth media. For a parallel set of 
LC50 assays, cells were grown in a minimal media of MEM 
plus 1% foetal bovine serum (FBS). The cells were split in 
6-well plates at 3–5 day intervals depending on confluence 
and cells were grown to 80% confluency in preparation for 
14 days treatment with cadmium chloride (CdCl2; 50 μM), 
based on our previously published data (Djordjevic et al 
2019).
Chemicals and antibodies
CdCl2, sterile dimethylsulfoxide, sterile phosphate-buffered 
saline, and molecular grade water were purchased as the 
highest grade required from Sigma-Aldrich (St. Louis, MO 
USA), Fisher Scientific (Houston, TX USA), and Pierce 
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Biotechnology (Rockford, IL USA). ELISA kits were 
obtained from Pierce Biotechnology (Rockford, IL USA). 
Antibodies were obtained from R&D Systems Inc., (Minne-
apolis, MN USA), Cell Signaling Technology, Inc. (Danvers, 
MA USA), and Thermo-Fisher Scientific (Waltham, MA 
USA). Media for each cell line were obtained from Corn-
ing Life Sciences (Tewksbury, MA USA). Media supple-
ments were purchased from Sigma-Aldrich (St. Louis, MO 
USA), and these included penicillin/streptomycin, glucose, 
glutamine, and sodium bicarbonate. Foetal bovine serum, 
triple 0.1 μm filtered, was purchased from Atlanta Biologi-
cals through R&D Systems (Minneapolis, MN USA).
LC50 assays to determine cadmium toxicity 
after 48 h exposure
Each of the five cell lines were plated at an initial density of 
20–50,000 cells/well and allowed to adhere for 24 h prior 
to the addition of  CdCl2. Cells were incubated for 48 h with 
increasing concentrations of  CdCl2 (12 concentrations, 
0—1 mM). After exposure, MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) stock solutions 
(11 mM in sterile PBS) were diluted in-well by the addition 
of 10 μL of MTT stock to each well (1.1 mM final concentra-
tion). Plates were returned to the incubator (37 °C/5%  CO2) 
for 4 h. After incubation, 50 μL of DMSO was added to each 
well to solubilize MTT crystals, and the plates were returned 
to the incubator for 30 min. Absorbance was measured using 
a Bio-Tek plate reader at 540 nm and is directly proportional 
to the number of live cells.
ELISA assays and protein detection
The human β-catenin kit was purchased from MyBioSource, 
Inc. (MBS266009; San Diego, CA USA), and was designed 
for measuring β-catenin from human-derived cells and cell 
supernatants. Cell preparation and assay protocols were 
essentially as described in the manufacturer’s protocol. The 
quantity of β-catenin in the sample extracts was extrapo-
lated from a standard curve using β-catenin concentrations 
of 0 pg/mL to 1000 pg/mL. Cell lysates were prepared 
after exposure to Cd for 48 h by trypsinization, centrifuga-
tion, and washing (3x) in PBS. The resulting cell suspen-
sion was subjected to three freeze–thaw cycles at − 20 °C. 
The suspension was centrifuged at 1000 ×g (or 3,000 rpm) 
for 15 min at + 2–4 °C to remove cellular debris. The final 
supernatant is ready for assay, or can be stored at − 80 °C 
until use. The amount of β-catenin present was quantified 
using a biotinylated β-catenin antibody (1:100 dilution).
In-Cell ELISA protocols for the remaining assays were 
based on the Pierce Biotechnology kit with the antibody 
either being provided in the kit, or purchased separately. The 
assay procedures are the same for each. Cells were exposed 
to 1 μM  CdCl2 for 48 h in a 37 °C/5%  CO2 incubator. After 
incubation, media are removed and 4% formaldehyde is 
added to each well to fix the cells. Cells are washed, perme-
abilized, quenched, and blocked in sequential fashion. The 
primary antibody is added, and the plated sealed and stored 
at + 4 °C overnight. The dilutions of each primary antibody 
were as follows: phospho-Akt (AF887, R&D Systems; 
1:2000); phosphatase and tensin homolog (PTEN) (AF847, 
R&D Systems; 1:1000); Poly (ADP-ribose) polymerase 
(PARP) (1861790, Thermo-Fisher; 1:1000); Forkhead box 
protein O1 (FOXO1) (2880S, Cell Signalling; 1:1,000); and 
tumour protein 53 (p53) (1861777, Thermo-Fisher; 1:1000). 
Following incubation overnight at + 4 °C, cells are removed, 
washed and a TMB solution (3,3′, 5,5;-tetramethylbenzidine) 
is added. TMB is a chromogen that can be used in place 
of horseradish peroxidase (HRP). Absorbance is measured 
using a Bio-Tek® plate reader and Gen5 software at 450 nm. 
To standardize the protein expression data, Janus Green 
whole-cell stain was used to account for potential differ-
ences in cell number between wells. Janus Green staining is 
measured by absorbance at 615 nm. Dividing the absorbance 
at 450 nm by the absorbance at 615 nm yields a relative 
protein expression.
Caspase 3/7 kinetic assays
Caspase 3/7 activity (measurement of apoptosis) was deter-
mined using the Apo-One™ Homogeneous caspase-3/7 
assay (Promega, Madison WI). Both Caspase 3 and 7 
convert the non-fluorescent substrate rhodamine 110, bis-
(N-CBZL-aspartyl-L-glutamyl-L-valyl-L-aspartic acid 
amide; Z-DEVD-R110), by removing the DEVD peptides. 
Removal of the DEVD peptide results in the rhodamine 110 
leaving group being excited at a wavelength of 499 nm with 
an emission wavelength of 521 nm. The fluorescence gener-
ated is directly proportional to the amount of caspase 3 and 7 
present. Cells were plated as described above and the treat-
ment was started with the addition of 1 μM  CdCl2. Plates 
are returned to the incubator for 48 h (37 °C/5%  CO2). After 
48 h exposure, caspase 3/7 activity was determined by the 
addition of 100 µL (1:1 with media) of the caspase 3/7 sub-
strate/buffer mix. Plates were wrapped in foil and returned to 
the incubator (37 °C/5%  CO2) for 1 h. Emitted fluorescence 
was measured using a Bio-Tek® plate reader and Gen5 soft-
ware at  485ex/530em. Additional readings were taken at 3 h 
and 6 h for kinetic assessment of caspase 3/7 activity.
RNA extraction and quantitative real‑time PCR
miR expression levels were assessed in non-treated and 
treated with  CdCl2 Panc-1 and MiaPaCa-2 PDAC cell lines. 
Panc-1 and MiaPaCa-2 cell lines were processed for RNA 
isolation, followed by cDNA translation and assessment for 
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the relative expression of miR-155, miR-221, and miR-126. 
RNA extraction was carried out using Trizol (Sigma, U.K.), 
while RNA concentration and purity were measured by Nan-
oDrop Spectrophotometry at 260 nm and 280 nm absorb-
ance. Reverse transcription of RNA to cDNA was carried 
out using the miRCURYâLNAâ RT Kit (Qiagen, U.K.). 
U6-snRNA was used as reference RNA to normalise miR 
expression levels. The miRCURYâ LNAâ miRNA SYBRâ 
Green (Qiagen, U.K.) was used in conjunction with MystiCq 
microRNA qPCR primers for miR-155 (hsa-miR-155-5p), 
miR-126 (hsa-miR-126-5p), and miR-221 (hsa-miR-221-5p), 
which were all obtained from Sigma (U.K.). The sequences 
for U6-snRNA primers were U6 forward, 5′-GCT TCG GCA 
GCA CAT ATA CTA AAA T-3′ and reverse 5′-CGC TTC ACG 
AAT TTG CGT GTCAT-3′ for both. The conditions for ther-
mocycling were: heat activation at 95 °C/2 min, followed 
by 40 cycles at denaturation at 95 °C/10 s and combined 
annealing/extension at 56 °C/60 s. The miR-155, miR-126, 
and miR-221 expression levels were normalised to that of 
U6 using the  2^ΔΔCT method. Normal cDNAs were gener-
ated using qScriptä cDNA Supermix (Quantabio, UK) with 
incubations at 22 °C for 5 min, 42 °C for 30 min, and 85 °C 
for 5 min, and the following genes were examined: Wnt-11, 
E-cadherin, Snail, and Zeb1. PrecisionâPlus qPCR Master 
Mix (Primer Design, UK) was used for RT-qPCR synthesis 
with the following thermocycling conditions for 40 cycles; 
95 °C for 2 min, 95 °C for 10 s, and 95 °C for 60 s. Relative 
levels of mRNA expression were calculated using the com-
parative CT/2−ΔΔCT method with RNA polymerase II (RPII) 
as the reference gene.
Statistical analysis
GraphPad Prism version 9.01 (GraphPad Software, San 
Diego, U.S.A.) was used for statistical analysis and prepara-
tion of graphs. Paired t tests were used to assess the expres-
sion levels of selected miRs and proteins compared with 
the controls. Experiments were carried out in triplicates for 
miRs and protein analysis. All non-miRNA data were ana-
lyzed using GraphPad Prism (v 9.1–9.3; San Diego, CA). 
Analyses include one-way ANOVA with the specialized 
Dunnett’s test for post hoc comparison to control values. 
Data analysis was accomplished using a two-way (Cell type 
× treatment) or three-way (Cell type × treatment × protein) 
ANOVA with Tukey’s test adjusted for multiple comparisons 
or Sidak’s post hoc comparison test, as listed. LC50 values 
were determined by fitting the data to a nonlinear curve fit-
ting, log concentration × response (three-parameter) single-
site model, to yield a sigmoid inhibition curve. All data are 
expressed as the mean ± standard deviation (SD) of 4–8 
assays performed in duplicate or triplicate were indicated. 
To test for data normality, the D’Agostino–Pearson omnibus 
test was performed. When the test yielded significant results, 
the data were deemed to be not normally distributed. For 
data that violated the assumption of normal distribution, the 
nonparametric Kruskal–Wallis test was performed, followed 
by a post hoc comparison using the corrected Dunn’s test. 
Significance is set at α = 0.05.
Results
In summary, we determined the LC50 value for  CdCl2 in 
multiple PDAC cell lines. One concern that needed to be 
addressed was the ability of complete growth media to 
potentially interfere with the action of the toxic metal. Par-
allel assays were performed, one in ATCC described growth 
media and another set in a minimal growth media with only 
1% FBS supplementation and no phenol. Interestingly, we 
found that there was no media effect in AsPC-1 cells, and 
the HPNE cells seemed to be more resistant to the lethal 
effect of  CdCl2. The remaining cell lines all responded with 
increased sensitivity to the lethal effects of  CdCl2 signifi-
cantly lowering the LC50 values in the presence of minimal 
media. When examining proteins associated with apoptotic 
processes, there were few  CdCl2-related effects, with the 
many of the differences being related to the cell line, and 
differences in either basal activity or expression. It may be 
of interest that in studies examining the expression of phos-
pho-Akt and β-catenin, tumour cells appeared to respond 
in the opposite direction as HPNE control cells suggesting 
the potential for differential responses. We further assessed 
the expression levels of specific miRs in response to  CdCl2 
exposure. The current study found that miR-221 and miR-
155 were upregulated in metastatic PDAC cell lines treated 
with  CdCl2, while miR-126 was downregulated. We have 
also noted that  CdCl2 altered the expression levels of EMT 
markers such as Wnt-11, E-cadherin, Snail, and Zeb1. Par-
ticularly, Wnt-11, Snail and Zeb1 were considerably upregu-
lated following  CdCl2 exposure, while E-cadherin expres-
sion level was decreased in PDAC cell lines treated with 
 CdCl2 compared to non-treated cells.
LC50 assays to determine cadmium toxicity 
after 48 h exposure
CdCl2 LC50 analysis in PDAC cells
Initial LC50 analysis to determine the lethality thresh-
olds was performed in optimum growth media which 
provides the cells with the required nutrients, and pro-
tectants, for optimum growth. Each of the cell lines were 
incubated with their optimum growth media as defined 
by ATCC. Cells were allowed to adhere for 24 h and the 
exposure was started by the addition of increasing con-
centrations of  CdCl2 and the cells were returned to the 
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incubator (37 °C/5%  CO2) for 48 h. We observed a reduc-
tion in cell viability with increasing concentrations of 
 CdCl2 (Fig. 1A). The shapes of the curves were best fit 
to a single-site model (three-parameter model). Between 
cell lines, there was a clear shift to the left for HPNE and 
AsPC-1 cells (lower LC50 values), whereas Panc-1, BxPC-
3, and Panc-10.5 cells were shifted 10–15-fold to the right 
(Fig. 1B). Kruskal–Wallis analysis revealed a significant 
difference in LC50 values between cell lines H(5) = 31.97; 
p < 0.0001. Using Dunn’s test for multiple comparisons, 
control HPNE LC50 values were significantly lower than 
Panc-1 (p < 0.01) and Panc-10.05 (p < 0.01). LC50 val-
ues for AsPC-1 cells were significantly lower compared 
to all other cancer lines, Panc-1 (p < 0.001), BxPC-3 
(p < 0.05), and Panc-10.05 (p < 0.0001). The compari-
sons between LC50 are also in Table1 where the assay 
media comparison is examined (Table  1). A lethal-
ity series can be obtained based on LC50 values, with 
AsPC-1 ≤ HPNE < BxPC-3 < Panc-1 = Panc-10.05. The 
maximum lethality at 1 mM  CdCl2 was compared across 
cell lines, and we observed significant differences across 
cell line H(5) = 37.22; p < 0.0001 (Fig. 1C). PDAC cells 
were more sensitive to the actions of  CdCl2 with AsPC-1, 
Panc-1, and BxPC-3 cells exhibiting almost 90% lethality. 
Control HPNE cells exhibited about 80% lethality at 1 mM 
 CdCl2, but Panc-10.05 cells were the most resistant with 
only about 70% lethality.
Fig. 1  Comparison of LC50 values in PDAC cells grown in opti-
mum growth media. Exposure to increasing concentrations of  CdCl2 
resulted in increased lethality in all PDAC cell lines. Cells were 
plated according to what is outlined in “Methods” and exposed 
to  CdCl2 for 48 h. Live cell numbers were determined by the MTT 
assay and the data were fit to a nonlinear curve fitting program using 
a single-site, three-parameter model. The best-fit curve for each of 
the assays is represented in (A). Individual curves were analyzed 
and LC50 values obtained to compare group LC50 values (B). When 
comparing LC50 values, the Panc-1, BxPC-3, and Panc-`0.05 cells 
are represented on the right axis. Maximum lethality in the presence 
of  CdCl2 occurred at concentrations greater than 1  mM. Therefore, 
(C) represents the maximum lethality of 1 mM  CdCl2 in each of the 
PDAC cell lines. Kruskal–Wallis analysis was used to assess differ-
ences in LC50 values between PDAC cell lines and Dunn’s test for 
multiple comparisons. Data represent a mean of eight (n = 8) assays 
performed in duplicate (mean ± SD). Exact p values are indicated (* 
p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001)
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Effect of minimal media on  CdCl2 LC50 values
A concern when performing toxicity studies in cell cul-
ture is trying to mimic the normal cellular environment as 
close to normal as possible. The use of optimum growth 
media provides the cells with the required nutrients, and 
protectants, for optimum growth. However, it is possible 
that some of the ingredients of the media can reduce the 
toxicity observed with environmental toxicants. Our par-
allel set of assays in a minimal media (MEM + 1% FBS) 
with reduced glutamine supplementation, and without 
phenol, could provide a different environment that would 
promote toxicity. We observed a reduction in cell viability 
with increasing concentrations of  CdCl2 (Fig. 2A). The 
shapes of the curves were similar to what was observed in 
optimum growth media, but the potency of  CdCl2 signifi-
cantly shifted (Fig. 2B). Kruskal–Wallis analysis revealed 
a significant difference in LC50 values between cell lines 
H(5) = 13.54; p = 0.0089. Using Dunn’s test for multiple 
comparisons, the only groups that were significantly dif-
ferent were HPNE and AsPC-1 (p = 0.0125) cell lines. 
Interestingly, the potency order between the cell lines was 
significantly different compared to what was observed 
in the optimum growth media (Table 1). The maximum 
lethality at 1 mM  CdCl2 was compared across cell lines, 
and we observed significant differences across cell line 
H(5) = 18.29; p = 0.0011 (Fig. 2C). PDAC cells were more 
sensitive to the actions of  CdCl2 with both Panc-1 and 
BxPC-3 cells exhibiting > 90% lethality. Control HPNE 
cells were the most resistant with about 75% lethality at 
1 mM  CdCl2.
Effect of Cd exposure on caspase 3/7 activity
We examined the activity of caspase-3, a critical executioner 
caspase, after exposure to  CdCl2 for 48 h. The rationale for 
examining caspase-3 activity was that they are pivotal for 
apoptosis and cell death. Normally, caspase-3 is found in a 
procaspase form, which is inactive. To activate, either extrin-
sic factors, death receptor stimulation, or intrinsic, mito-
chondrial damage, will trigger the activation of caspase-3. 
Time-course analysis was performed and the ability of cas-
pase-3 to cleave Z-DEVD-NH from rhodamine 110, result-
ing in a fluorescent signal that is proportional to the amount 
of caspase-3 present. Caspase-7 also recognized the DEVD 
bond, so the data are expressed as caspase-3/7 activity. We 
measured the activity of caspase-3/7 at for 1, 3, or 6 h after 
a 48 h exposure to  CdCl2 (Fig. 3A).
Expression of cleaved caspase-3 (active caspase) was 
determined by ELISA (Fig. 3B). There was a significant 
effect dependent on cell line type for cleaved caspase-3 
expression  (F4,30 = 25.87; p < 0.0001). We also observed a 
significant effect related to  CdCl2 exposure across all cell 
lines  (F1,30 = 5.288; p = 0.028). The trend was for  CdCl2 
exposure to cause a reduction in expression, with basal 
expression of cleaved caspase 3 being significantly lower 
in Panc-1 (p < 0.0001) and BxPC-3 (p = 0.0044) cells com-
pared to control HPNE cells.
Effect of Cd exposure on the expression of proteins 
associated with apoptosis
We examined the expression of several proteins associated 
with apoptosis, many of which are implicated in the progres-
sion of PDAC. There was a consistent significant main effect 
across each of the cell lines regardless of the protein that is 
being examined. Data analysis was carried out using a three-
way ANOVA followed by Tukey’s multiple comparison post 
hoc test. Expression of phospho-Akt (Fig. 4A) was clearly 
different between cell lines  (F4,30 = 29.84; p < 0.0001), Post 
hoc analysis comparison test demonstrated that control 
HPNE cell expression of phospho-Akt was significantly 
higher than the control group in each of the tumour cell 
lines. PTEN (Fig. 4B) expression was significantly affected 
by 48 h exposure to  CdCl2 with a significant main effect 
of both treatment  (F1,30 = 17.03; p = 0.0003) and cell line 
 (F4,30 = 106.5; p < 0.0001). There was also a significant 
cross-over interaction  (F4,30 = 8.12; p = 0.0001). The cross-
over interaction is evident by the slight decline in PTEN 
expression in the control HPNE cells following  CdCl2 
exposure, compared to slight increases in PTEN expression 
across the tumour cell lines. Expression of PARP (Fig. 4C) 
was only slightly affected by  CdCl2 exposure. There was 
a significant effect of cell line type on PARP expression 
Table 1  Comparison of LC50 values in ATCC-defined optimum 
growth media compared to minimal MEM media with 1% FBS
Dunn’s test for multiple comparisons was used to assess control 
HPNE LC50 values compared with the selected PDAC cell lines 
(AsPC-1, Panc-1, BxPC-3, and Panc-10.05). Exact p values are indi-
cated (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001)
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 (F4,30 = 6.14; p = 0.001). There were no differences between 
control and  CdCl2 exposure in any cell line.
For the quantification of β-catenin, we were able to 
directly measure the amount of β-catenin in the cell lysates 
(Fig. 4D). In control HPNE cells,  CdCl2 exposure for 48 h 
resulted in a 50% increase in β-catenin, but this difference 
was not significant. We observed a significant effect of cell 
line type on β-catenin content  (F4,20 = 5.94; p = 0.0026) 
with a significant cross-over interaction with treatment 
 (F4,20 = 3.1; p = 0.039). Generally, tumour cells exhib-
ited a higher basal level of β-catenin, with AsPC-1 cells 
demonstrating nearly double the basal level of β-catenin 
compared to control HPNE cells (p = 0.0028). We exam-
ined the effect of  CdCl2 exposure on FOXO1 expression 
(Fig. 4E) due to the involvement of the FOXO proteins and 
sirtuin 1 (SIRT1) in glucose handling, development of dia-
betes, and potential role in the development of PDAC. There 
was a significant  (F4,29 = 21.54; p < 0.0001) effect of cell line 
type on the expression of FOXO1 with both BxPC-3 and 
Panc-10.05 demonstrating a twofold increase compared to 
control HPNE cells. There was a significant effect of treat-
ment  (F1,29 = 15.88; p = 0.0004) across cell lines with  CdCl2 
Fig. 2  Comparison of LC50 values in PDAC cells exposed to  CdCl2 
in minimal (MEM + 1% FBS) media. Exposure to increasing concen-
trations of  CdCl2 resulted in increased lethality in all PDAC cell lines. 
Cells were plated according to what is outlined in “Methods” and 
exposed to  CdCl2 for 48 h. Live cell numbers were determined by the 
MTT assay and the data were fit to a nonlinear curve fitting program 
using a single-site, three-parameter model. The best-fit curve for each 
of the assays is represented in (A). Individual curves were analyzed 
and LC50 values obtained to compare group LC50 values (B). Max-
imum lethality in the presence of  CdCl2 occurred at concentrations 
greater than 1 mM. Therefore, (C) represents the maximum lethality 
of 1 mM  CdCl2 in each of the PDAC cell lines. Kruskal–Wallis analy-
sis was used to assess differences in LC50 values between PDAC cell 
lines and Dunn’s test for multiple comparisons. The data represent 
a mean of eight (n = 4) assays performed in duplicate (mean ± SD). 
Exact p values are indicated (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; 
**** p ≤ 0.0001)
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exposure reducing FOXO1 expression, but this change only 
reached significance in the Panc-10.05 cell line. Finally, 
we measured the expression of p53 (total) in PDAC cells 
(Fig. 4F) and observed a significant effect of cell line type on 
the expression  (F4,30 = 218.0; p < 0.0001). Exposure to  CdCl2 
had no effect on p53 expression across each of the cell lines. 
Basal level of p53 expression was significantly elevated 
compared to HPNE control cells in Panc-1 (p < 0.0001), 
BxPC-3 (p < 0.0001), and Panc-10.05 (p < 0.01) cells.
MicroRNAs’ expression levels are differently 
modulated in response to cadmium treatments 
in PDAC cells
Following the effect of the  CdCl2 in apoptosis, we then 
continued to investigate its role in miR expressions. Based 
on our previous and others studies, specific miRs including 
miR-221, miR-155, and miR-126 are closely associated with 
the development of PDAC in different stages (Greither et al. 
2010; Komoto et al. 2009; Su et al. 2013; Uysal-Onganer 
et al. 2021). Therefore, when assessing miRs expression 
levels (miR-155, miR-221, miR-126), significant expres-
sion changes were observed in response to  CdCl2 treatment. 
Our current study showed that in the Panc-1 cell line,  CdCl2 
treatment significantly upregulated the mRNA expression 
levels of miR-221 by 65% (n = 3; p < 0.001; Fig. 5A) and 
miR-155 mRNA expression levels by 30% (n = 3; p < 0.05; 
Fig. 5B) compared to non-treated PDAC cells (control cells). 
Expression levels of miR-125 significantly downregulated 
by 100% (n = 3; p < 0.0001; Fig. 5C) in the same PDAC cell 
line. Similarly, our results found that in the MiaPaCa-2 cell 
line, mRNA expression levels of miR-221 (n = 3; p < 0.05; 
Fig. 5D) and miR-155 (n = 3; p < 0.05; Fig. 5E) were sig-
nificantly increased by 33.5% and by 17%, respectively, 
following  CdCl2 exposure, while mRNA expression lev-
els of miR-126 were significantly reduced by 84% (n = 3; 
p < 0.001; Fig. 5F).
Cadmium treatment differently affects Wnt‑11, 
E‑cadherin, Snail, and Zeb1 protein levels in Panc‑1 
and MiaPaCa‑2 cells, following 14 days treatment
According to our previous and other reports, EMT markers 
play a significant role in different biological processes such 
as invasion and metastasis during PDAC development (Aru-
mugam et al. 2009; Dart et al. 2019; Hotz et al. 2007; Iac-
obuzio-Donahue et al. 2009; Wang et al. 2018a, b). There-
fore, based on our previous study, we extensively exposed 
both Panc-1 and MiaPaCa-2 PDAC cell lines with  CdCl2 
for 14 days, to further assess the protein levels of Wnt-11, 
Fig. 3  Changes in Caspase 3/7 activity at 1, 3, and 6 h (A) and the 
expression of cleaved caspase 3 (B) following 48 h  CdCl2 exposure. 
After 48  h exposure, caspase 3/7 activity was determined using the 
Apo-One™ Homogeneous caspase-3/7 assay. The fluorescence gen-
erated in this kit is directly proportional to the amount of caspase 3 
and 7 present. Fluorescence was measured at 1, 3, and 6 h after the 
addition of the non-fluorescent substrate (A). Emitted fluorescence of 
the product was measured using a Bio-Tek ® plate reader and Gen5 
software at  499ex/521em. The amount of cleaved caspase 3 expressed 
was measured with a modification of the Pierce assay kit. After 48 h 
exposure, media were removed and 4% formaldehyde added to fix the 
cells in the wells. Primary antibody for cleaved caspase (Invitrogen; 
PA5-23921) was diluted 1:1,000, added to the fixed cells, and stored 
at + 4 °C overnight. After TMB administration, absorbance was meas-
ured at 450 nm. Cells were stained with Janus Green to account for 
differences in cell number between wells and absorbance read at 
615  nm. Dividing the absorbance at 450  nm by the absorbance at 
615 nm yields a relative protein expression. Two-way ANOVA with 
Tukey’s post hoc analysis was used to examine the expression lev-
els of Caspase 3/7 activity in the selected PDAC cell lines following 
exposure to  CdCl2. The data represent a mean of four (n = 4) assays 
performed in duplicate (mean ± SD). Exact p values are indicated (* 
p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001)
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E-cadherin, Snail, and Zeb1 by RT-qPCR (Djordjevic et al. 
2019). In our current study, we found that in both PDAC 
cell lines,  CdCl2 significantly upregulated Wnt-11, Snail, 
and Zeb1 expression levels and considerably reduced E-cad-
herin protein levels compared to non-treated PDAC cell 
lines (Fig. 6). Specifically, our results indicated that in the 
Panc-1 cell line, the mRNA expression levels of Wnt-11% 
(n = 3; p < 0.001; Fig. 6A), Snail (n = 3; p < 0.001; Fig. 6C), 
and Zeb1 (n = 3; p < 0.0001; Fig. 6D) were significantly 
increased by 47%, 38%, and 42%, respectively, following 
 CdCl2 exposure compared with the non-treated Panc-1 cells 
(Panc-1 control cells), while mRNA expression levels of 
E-cadherin (n = 3; p < 0.0001; Fig. 6B) were significantly 
decreased by 62% in the same PDAC cell line. Similarly, 
in the MiaPaCa-2 cell line, the mRNA expression levels 
of Wnt-11 (n = 3; p < 0.01; Fig. 6E), Snail (n = 3; p < 0.01; 
Fig. 6G), and Zeb1 (n = 3; p < 0.0001; Fig. 6H) were signifi-
cantly overexpressed by 50%, 28%, and 29%, respectively, 
following  CdCl2 exposure compared with the non-treated 
MiaPaCa-2 cells (MiaPaCa-2 control cells), while mRNA 
expression levels of E-cadherin (n = 3; p < 0.0001; Fig. 6F) 
were significantly reduced by 47% in the same PDAC cell 
line.
Discussion
The main outcome of our current study is that there is a 
strong correlation between  CdCl2 exposure, miR expression, 
and protein expression associated with apoptosis.
Our study has methodically examined the effects of 
 CdCl2 on the expression of multiple proteins associated with 
apoptotic pathways and as well as the expression of miRs 
that are involved in the cancer development and changes to 
apoptotic responses. We observed that  CdCl2 exposure for 
48 h exhibited a high degree of lethality on each of the cell 
lines with LC50 values 3–100 μM in normal growth media. 
In a reduced, or minimal, media, these values changed to 
5–20 μM. The maximum lethality in all cell lines ranged 
from 70 to 85% at 1 mM  CdCl2. We, and others, have shown 
that Cd itself is a weak pro-oxidant (Buha et al. 2017; Chen 
et al. 2011; Liu et al. 2009; Martinez-Zamudio and Ha 2011; 
Fig. 4  Changes in protein expression following 48  h exposure to 
 CdCl2. Proteins associated with cell function and apoptosis were 
selected and the expression of phospho-Akt (A), PTEN (B), PARP 
(C), β-catenin (D), FOXO1 (E), and total p53 (F) were measured. 
The amount of cleaved caspase 3 expressed was measured with a 
modification of the Pierce assay kit as described in ‘Methods’. After 
48 h exposure, media were removed and 4% formaldehyde added to 
fix the cells in the wells. Primary antibodies were diluted 1:500—
1:2,000, added to the fixed cells, and stored at + 4 °C overnight. After 
TMB administration, absorbance was measured at 450  nm. Cells 
were stained with Janus Green to account for differences in cell num-
ber between wells and the absorbance read at 615 nm. Dividing the 
absorbance at 450 nm by the absorbance at 615 nm yields a relative 
protein expression. Three-way ANOVA followed by Tukey’s multiple 
comparison post hoc test was used to assess the expression levels of 
PTEN, PARP, β-catenin, FOXO1, and p53 following 48 h exposure to 
 CdCl2 compared with the non-treated PDAC cells. The data represent 
a mean of four (n = 4) assays performed in duplicate (mean ± SD). For 
the β-catenin assays, the data represent a mean of three (n = 3) assays 
performed in duplicate (mean ± SD). Exact p values are indicated (* 
p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001)
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Waisberg et al. 2003; Wallace et al. 2019). The ability to 
induce oxidative stress would be one mechanism in tumour 
development. We investigated multiple proteins associated 
with apoptosis, cell death, cellular repair, and growth regula-
tion. Included in this group was cleaved caspase-3, phospho-
Akt, PARP, PTEN, β-catenin, FOXO1, and p53. The major 
differences occurred between cell lines, with differing levels 
of expression. The main  CdCl2 effects are observed with 
PTEN and FOXO1 expression with  CdCl2 exposure result-
ing in increased expression of PTEN in both Panc-1 and 
Panc-10.05 cell lines. FOXO1 expression in Panc-10.05 was 
significantly reduced following exposure to  CdCl2.
The miRs response in humans after Cd exposure is very 
complex, especially having in mind Cd ability to bioaccu-
mulate in the body. So far, changes in miRs in terms of both 
up and downregulation were identified in ovarian granu-
losa cells (Wang et al. 2018a, b), kidneys (Pellegrini et al. 
2016), prostate epithelial cells (Ngalame et al. 2016), hepatic 
cell lines (Urani et al. 2014), and bronchial epithelial cells 
(Liu et al. 2015). In our current study, we found that miRs 
expression levels have been significantly altered in PDAC 
cells lines treated with Cd from control cells. In particu-
lar, miR-221 and miR-155 expressions were considerably 
overexpressed in both Panc-1 and MiaPaca-2 PDAC cell 
lines treated with  CdCl2, while miR-126 was significantly 
reduced.
As an oncogenic miR, miR-221 has been related to sev-
eral epithelial cancers such as glioma (Lu et al. 2009; Siegel 
et al. 2014; Zhang et al. 2009, 2012), prostate carcinoma 
(Mercatelli et al. 2008), hepatocellular cancer (Gramantieri 
et al. 2009), and lung cancer (Garofalo et al. 2008), while 
the upregulation of this miR has been also linked to PDAC 
cell lines and tumour tissues in comparison to normal pan-
creatic tissues (Papaconstantinou et al. 2013). Other studies 
have highlighted that miR-221 not only upregulated in the 
MiaPaCa-2 cell line compared to normal human pancreatic 
ductal epithelium (Zhang et al. 2008), but also alterations in 
its expression levels can promote the metastatic propensity 
Fig. 5  CdCl2 treatment-medi-
ated effects on miR mRNA 
expression levels in PDAC 
cells. (A–C) Effects of  CdCl2 
exposure in the Panc-1 cell line: 
(A) miR-221 mRNA expression 
levels; (B) miR-155 mRNA 
expression levels; (C) miR-126 
mRNA expression levels. (D–F) 
Effects of  CdCl2 exposure in the 
MiaPaCa-2 cells (D) miR-221 
mRNA expression levels; (E) 
miR-155 mRNA expression 
levels; (F) miR-126 mRNA 
expression levels. The column 
graphic represents the average 
of three replicates of RNA iso-
lated from each cell line. Data 
normalised according to RNU6 
expression by fold analysis 
(n = 3, p < 0.05). Paired t test 
was used to examine the mRNA 
expression levels of the selected 
miRs following  CdCl2 treatment 
compared with the non-treated 
PDAC cells (control cells). 
Exact p values are indicated 
(* p ≤ 0.05; ** p ≤ 0.01; *** 
p ≤ 0.001; **** p ≤ 0.0001); 
error bars indicate SD
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of PDAC cell lines (Xu et al. 2015). According to previous 
findings, upregulation of miR-221 is common in PDAC tis-
sue samples compared to normal controls and, therefore, 
the expression of miR-221 in PDAC could be used for the 
discrimination of PDAC from benign PDAC tissue with 
specificity 93% (Bloomston et al. 2007). Importantly, when 
assessing the expression levels of miR-221 in the current 
study, miR-221 was identified to be significantly upregu-
lated more in PDAC cells treated with  CdCl2 compared with 
the non-treated PDAC cell, which highlighting that  CdCl2 
exposure increased the oncogenic property of miR-221 in 
PDAC cells. miR-155 is a further example of oncogenic 
miR, which is highly upregulated in several solid malignan-
cies such as breast, colon, and thyroid cancers (Babar et al. 
2011; Bakirtzi et al. 2011; Jiao et al. 2012; Nikiforova et al. 
2008). Recent studies have indicated that miR-155 is one of 
the most oncogenic miR in PDAC (Bloomston et al. 2007; 
Szafranska et al. 2007), which is linked to poor prognosis of 
PDAC (Greither et al. 2010). miR-155 upregulation is also 
associated with PanIN-2 and PanIN-3 lesions compared to 
healthy pancreatic tissue (Ryu et al. 2010) and its upregula-
tion was noticed in 80% of early pancreatic lesions (Ryu 
et al. 2010). In our current study, upregulated expression 
of miR-155 was found in both Panc-1 and MiaPaCa-2 cells 
treated with  CdCl2 compared with the control  cells, which 
indicates a correlation between  CdCl2 exposure and the 
oncogenic capability of miR-155. It has been also reported 
that the tumour suppressor miR-126 is correlated to numer-
ous malignancies including lung, gastric, breast, and PDAC 
cancer (Feng et al. 2010; Sempere et al. 2010; Zhou et al. 
Fig. 6  CdCl2 treatment-mediated effects on protein mRNA expres-
sion levels in PDAC cells. (A–D) Effects of  CdCl2 exposure in the 
Panc-1 cell line: (A) Wnt-11 mRNA expression levels; (B) E-cad-
herin mRNA expression levels; (C) Snail mRNA expression levels; 
(D) Zeb1 mRNA expression levels. (E–G) Effects of  CdCl2 exposure 
in the MiaPaCa-2 cells; (D) Wnt-11 mRNA expression levels; (E) 
Wnt-11 mRNA expression levels; (F) E-cadherin mRNA expression 
levels; (G) Snail mRNA expression levels; (H) Zeb1 mRNA expres-
sion levels. The column graphic represents the average of three rep-
licates of RNA isolated from each cell line. Data normalised accord-
ing to RPII expression by fold analysis (n = 3, p < 0.05). Paired t tests 
were used to examine the mRNA expression levels of the selected 
proteins following  CdCl2 treatment compared with the non-treated 
PDAC cells (control cells). Exact p values are indicated (* p ≤ 0.05; 
** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001); error bars indicate SD
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2016). Specifically, reduced expression levels of miR-126 
can lead to cellular migration and invasion through the inhi-
bition of ADAM metallopeptidase domain 9 (ADAM9) target 
gene, which is commonly expressed in PDAC (Grutzmann 
2004). Therefore, the reduced expression of miR-126 in 
PDAC has been reported in the previous studies, and this 
can be also associated with the results of our current study, 
which showed that mRNA expression levels of miR-126 
was significantly decreased following  CdCl2 exposure in 
the Panc-1 and MiaPaCa-2 cell lines.
In the current study, we also found that Cd regulates 
EMT and dysregulates the expression levels of mesenchy-
mal markers including Wnt-11, E-cadherin, Snail, and Zeb1. 
Specifically, expression of Wnt-11, Snail, and Zeb1 was sig-
nificantly overexpressed following the treatment with  CdCl2, 
whereas E-cadherin was reduced in PDAC cell lines treated 
with  CdCl2. miRs can promote not only proliferation and 
tumourigenesis in PDAC, but also to affect tumour micro-
environment (Fathi et al. 2021). Specifically, hypoxia and 
dysregulations in the expression levels of EMT markers can 
be altered by several miRs (Lu et al. 2017). Consequently, 
carcinogenesis can be modulated by certain miRs and signal-
ling cascades including Hedgehog, PTEN/Akt, Wnt, Signal 
transducer, and activator of transcription 3 (STAT3), ERK, 
JNK, TGF-β, and NF-κ (Fathi et al. 2021). EMT can be 
described as a morphologic cellular program, which repre-
sents the phenotypic transition from an epithelial to a mes-
enchymal state that is metastable (Wang et al. 2017). EMT 
is regulated by numerous complex modulatory networks 
such as epigenetic alterations, transcriptional control, which 
comprise EMT-inducing transcription factors (EMT-TFs) as 
Snail (Zinc finger protein SNAIL), Zeb (Zinc finger E-box-
binding homeobox 1), and transcription regulators including 
miRs (Wang et al. 2017). Especially, miRs are considered as 
main regulators of EMT in several cancer types but also as 
novel early biomarkers in PDAC (Ali et al. 2015; Balleha-
ninna and Chamberlain 2013; Calatayud et al. 2017; Chang 
and Kundranda 2017; Dhayat et al. 2015; Gayral et al. 2014; 
Sethi et al. 2018; Winter et al. 2013). Specifically, miRs can 
regulate EMT through the control of their target messen-
ger RNAs (mRNA) such as the E-cadherin transcriptional 
repressor ZEB-1 (Brabletz et al. 2011; Li et al. 2010; Krebs 
et al. 2017; Tang et al. 2016). For example, miR-200, miR-
141, miR-200a, miR-200b, miR-200c, miR-429 (Gregory 
et al. 2008; Humphries and Yang 2015; Mongroo and Rustgi 
2010), miR-34a (Ahn et al. 2012; Alemar et al. 2016; Tang 
et al. 2017), miR-148a (Feng et al. 2016; Peng et al. 2017; 
Tan et al. 2018, 2017), miR-203a (Jiang et al. 2017; McCu-
brey et al. 2016; Yang et al. 2017), and miR-655 (Harazono 
et al. 2013) act as EMT suppressors and negative regula-
tors of metastatic predisposition of PDAC cells (Gregory 
et al. 2008; Peter et al. 2009), while miR-10b (Ouyang et al. 
2014) and miR-197 (Hamada et al. 2013) strongly promote 
EMT. Particularly, miR-200 can inhibit the main regulators 
of EMT such as Zeb1 and Snail, which further results in the 
overexpression of E-cadherin levels (Gregory et al. 2008; 
Peter et al. 2009). Moreover, upregulation of miR-200c is 
linked not only to E-cadherin expression in resected human 
pancreatic tumour samples but also in better survival rates 
in comparison to patients with reduced miR-200c levels (Yu 
et al. 2010). Furthermore, Zeb1 can also suppress miR-200c 
and miR-141 transcription, which further contributes to the 
differentiation state of PDAC cells (Burk et al. 2008). Fur-
thermore, miR-200 family can also inhibit Notch signalling, 
which is responsible for tissue homeostasis and is closely 
linked to EMT through the overexpression of Notch signal-
ling and Zeb1 and decrease of miR-200 family in PDAC 
(Brabletz et al. 2011). A previous study showed that Zeb1 
is a key target of miR-655, which is an EMT-suppressor 
miR that is correlated to favorable overall survival in PDAC 
patients (Harazono et al. 2013). Ahn et al., (2012) also indi-
cated that miR-34a acts as a target of ZEB-1, which leads to 
the reduction of invasion and metastasis.
The downregulation of E-cadherin in PDAC patients has 
been widely described by the previous studies, which sug-
gested that the loss of E-cadherin expression is detected in 
43% of PDAC patients and associated with poor outcome 
and increased invasion and aggressiveness (Hong et al. 
2011). The results of this study showed that the mRNA 
expression levels of E-cadherin were significantly reduced 
following the exposure of PDAC cells to CdCl2, which 
points out the importance of assessing the role of CdCl2 
in EMT pathways during PDAC progression. Importantly, 
recent studies have suggested that Zeb1 and Snail overex-
pression is closely associated with PDAC progression and 
especially with inhibition of apoptosis and chemoresist-
ance against gemcitabine in PDAC (Li et al. 2009; Vega 
et al. 2004; Yin et al. 2007). Based on this information, 
the results of the current study, which showed a significant 
upregulation of these EMT markers following  CdCl2 expo-
sure in PDAC cells, indicate the importance of  CdCl2 in the 
regulation of these key tumourogenic PDAC EMT proteins. 
Additionally, other reports showed that Wnt-11 can enhance 
EMT, aggressiveness and migration in PDAC, which fur-
ther affects the survival rates in PDAC patients (Dart et al. 
2019). Specifically, Wnt-11 downregulation can promote 
not only EMT but also the expression levels of neuronal 
and stemness markers, which are linked to metastasis (Dart 
et al. 2019). In our current study, we particularly found that 
the mRNA expression levels of Wnt-11 were significantly 
overexpressed in Panc-1 and MiaPaCa-2 cells treated with 
 CdCl2 compared to the control cells; which promote pilot 
insights into the role of  CdCl2 in the Wnt-11 pathways. Con-
clusively, the Wnt family has been considered to be associ-
ated with TNM staging and especially with early stages of 
PDAC progression (Dart et al. 2019; Wang et al. 2018a, b; 
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Wang et al. 2016), and plays a crucial role as regulator of 
stemness, EMT, and invasiveness of several cancer types 
comprising PDAC (Dart et al. 2019; Murillo-Garzón et al. 
2018; Wei et al. 2014).
The existing evidence is clear, exposure to  CdCl2, results 
in cellular damage that can lead to the development of 
PDAC. We have observed cellular effects consistent with 
changes in the expression of select miRs that are involved 
in tumour development. We have also observed changes 
in protein expression that may contribute to PDAC forma-
tion. Normal pancreatic function is maintained by normal 
functioning of various miRs. Multiple miRs have important 
roles in normal insulin function and sensitivity, diabetes, and 
PDAC development (Chakraborty et al. 2013). Examining 
the different pathways and potential overlap between cellular 
signalling mechanisms, relationships between miRs/gene/
protein expression become evident. FOXO1 has been shown 
to inhibit the growth of tumours and can promote apopto-
sis (Mou et al. 2017). This is interesting considering  CdCl2 
exposure tended to reduce FOXO1 expression which would 
result in tumour growth. Data have shown that FOXO1, and 
other forkhead box transcription proteins, can increase the 
expression of pro-apoptotic genes and interfere with path-
ways utilizing Wnt/β-catenin, Akt, and PTEN, and is indi-
rectly regulated by miR-221 (Lima et al. 2011; Mou et al. 
2017). In breast cancer, miR-221 can work through both 
modulating the estrogen receptor gene, and FOXO1 expres-
sion (Mou et al. 2017). miR-221 regulates a target, Dick-
kopf 2, subsequently inhibiting the activation of the Wnt/β-
catenin pathways (Chen et al. 2020). An inverse relationship 
between miR-221 and FOXO1 (downregulation of miR-221/
upregulation of FOXO1) has been reported in ovarian cells 
in menopause (Wei et al. 2021). Overexpression of miR-221 
can directly increase the growth and proliferation of PDAC 
cells by downregulating PTEN expression and upregulating 
phospho-Akt expression (Yang et al. 2016). The upregula-
tion of miR-221 observed in our study did not translate to 
a reduction in PTEN and an increase in phospho-Akt. The 
tumour cell lines did show a slight increase in phospho-Akt 
expression following  CdCl2 exposure, but no downregula-
tion of PTEN expression. Downregulation of miR-221 will 
result in an increased expression of PTEN, as well as p27, 
p57, and PUMA which inhibits the growth and proliferation 
of PDAC cells (Park et al. 2009; Sarkar et al. 2013; Song 
et al. 2019). The regulation of p53 involves both positive and 
negative regulation, and the ability of p53 to regulate the 
expression of other miRs. Key miRs involved with p53 func-
tion are miR-34, miR-29, and miR-125 (Lima et al. 2011). 
Khakinezhad-Tehrani et al. (2021) reported that when miR-
221 was suppressed, pro-apoptotic proteins such as p53 were 
overexpressed and the tumour suppressor, miR-34, was also 
overexpressed. The miR-221-mediated changes in p53 and 
miR-34 expression could then interact with FOXO protein 
expression and SIRT1 activity. p53 can stimulate miR-29, 
which inhibits PI3K and reducing expression and activity of 
Akt (Otsuka and Ochiya 2014). P53 directly and indirectly 
interacts with SIRT1 via miR-34, while SIRT1 can interact 
with FOXO proteins (Otsuka and Ochiya 2014; Yamakuchi 
2012).
Conclusion
PDAC is the most fatal malignancy, and therefore, it is cru-
cial to develop a significant body of knowledge in the field 
of PDAC carcinogenesis. The role of environmental pol-
lutants, such as Cd, in PDAC have been suggested but still 
not fully understood. This is the first research to indicate 
the role of miRs in response to Cd in PDAC, suggesting a 
significant correlation between miRs and Cd exposure dur-
ing PDAC progression. These studies have also begun to 
establish a connection between apoptotic protein regulation, 
miRs, and Cd exposure in PDAC. Further studies are needed 
to investigate the precise role of miRs in PDAC progression 
as well as the role of Cd and other environmental pollutants 
in such processes. Furthermore, epigenetic data should be 
incorporated into risk assessments for Cd exposures improv-
ing our ability to predict outcomes and define more efficient 
prevention measures.
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